# Avrobio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avrobio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.avrobio.com
- Total disclosed funding: $85M
- Latest round: Series B (Feb 1, 2018)
- Investors on record: 9

## About

Founded in 2015 and based in Massachusetts, US, Avrobio, Inc. operates as a biopharmaceutical company that develops and manufactures cell and gene therapies for the treatment of cancer and rare diseases.

## Funding rounds

- Series B, Feb 1, 2018, $60M — Atlas Venture, SV Health Investors, Clarus Ventures, Aisling Capital, 5Y Capital, Surveyor Capital, Cormorant Asset Management, Eventide Asset Management, Brace Pharma Capital
- Series A, Aug 2, 2016, $25M — Atlas Venture, SV Health Investors, Clarus Ventures
- Seed, Feb 18, 2016 — Atlas Venture

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A, Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Surveyor Capital — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series B